Analysis of the EAP, page-345

I wonder what do you think about the economic cost vs treatment benefit of COPD. This Phase2 trial used monthly injection of 100mil cells for 4 months, but the most significant effect was shown at 4 months (day 120) and wear out after.

I had a look at the prognosis of end-stage COPD, in terms of mortality, Stage 3-4 COPD reduce life expectancy of a 65 yo smoker by an average of 5.8 years, for non smoker it reduces a mere 1.3 years. https://www.healthline.com/health/copd/life-expectancy#mortality-rates

Of course the treatment would significantly improve the quality of life for these patients for a short period of time, but with the cost equal if not more than to the cost of treating Covid ARDS (using ~360 million cells for a 90kg adult), i wonder if the cost justify the benefit.

However, this announcement today is significant, because we have more evidence that MSCs will likely produce positive results in Covid ARDS trial and MSCs might be able to treat most conditions with increased CRP, which is a hallmark of A LOT of inflammatory conditions.

Finally, Did anyone noticed SI's answer on Jason Folger's question during the conference call: "Beyond that, there's the opportunity to use the product for not just to COVID-19 but in Influenza ARDS and more broader causes of ARDS including, sepsis, bacterial sepsis, etc."

Am I the only one that is excited about sepsis and bacterial sepsis? As I have mentioned previously Takeda wanted to patent the use of MSCs for sepsis (patent pending). The prevalence of sepsis in US is estimated to be 300 per 100,000 and a mortality rate of up to 50%. I am glad that SI seems to always be a few steps ahead of everyone in the game.